Adenosine causes short-lasting vasodilation and headache but not migraine attacks in migraine patients: a randomized clinical trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Adenosine causes short-lasting vasodilation and headache but not migraine attacks in migraine patients : a randomized clinical trial. / Thuraiaiyah, Janu; Al-Karagholi, Mohammad Al-Mahdi; Elbahi, Fatima Azzahra; Zhuang, Zixuan Alice; Ashina, Messoud.
In: Pain, Vol. 164, No. 5, 2023, p. 1118-1127.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adenosine causes short-lasting vasodilation and headache but not migraine attacks in migraine patients
T2 - a randomized clinical trial
AU - Thuraiaiyah, Janu
AU - Al-Karagholi, Mohammad Al-Mahdi
AU - Elbahi, Fatima Azzahra
AU - Zhuang, Zixuan Alice
AU - Ashina, Messoud
N1 - Copyright © 2022 International Association for the Study of Pain.
PY - 2023
Y1 - 2023
N2 - Migraine is a common disabling disease with a complex pathophysiology. Headache is a frequent side effect after intravenous adenosine administration, although adenosine receptor antagonist, caffeine, relieves migraine headache. These observations suggest a possible involvement of adenosine signaling in headache and migraine pathophysiology. In a randomized, double-blinded, placebo-controlled, crossover study, 18 participants diagnosed with migraine without aura received 120 µg/kg per minute adenosine or placebo over 20 minutes. Headache intensity, migraine-associated symptoms, vital signs, the diameter of the superficial temporal artery (STA), blood flow velocity in the middle cerebral artery (V MCA ), and facial skin blood flow were measured at baseline and every 10 minutes until 2 hours after infusion start. The primary end point was the difference in the incidence of migraine attacks after adenosine infusion compared with placebo. Eighteen participants completed the study. We found no difference in the incidence of migraine after adenosine infusion (7 of 18, 39%) compared with placebo (3 of 18, 17%) ( P = 0.29). Fourteen participants reported headache after adenosine infusion (14 of 18, 78%) compared with placebo (6 of 18, 33%) ( P < 0.01). Adenosine increased heart rate ( P < 0.001), facial skin blood flow ( P < 0.05), and STA diameter (AUC T0-20min , P = 0.01) and decreased V MCA (AUC T0-20min , P < 0.001) compared with placebo. Adenosine induced headache accompanied by a short-lasting (<30 minutes) dilation of intracerebral and extracerebral arteries. The nonsignificant migraine induction might be because of the presence of several adenosine receptors with counteracting signaling, highlighting the need of more selective modulators to dissect the implication of adenosine in migraine.
AB - Migraine is a common disabling disease with a complex pathophysiology. Headache is a frequent side effect after intravenous adenosine administration, although adenosine receptor antagonist, caffeine, relieves migraine headache. These observations suggest a possible involvement of adenosine signaling in headache and migraine pathophysiology. In a randomized, double-blinded, placebo-controlled, crossover study, 18 participants diagnosed with migraine without aura received 120 µg/kg per minute adenosine or placebo over 20 minutes. Headache intensity, migraine-associated symptoms, vital signs, the diameter of the superficial temporal artery (STA), blood flow velocity in the middle cerebral artery (V MCA ), and facial skin blood flow were measured at baseline and every 10 minutes until 2 hours after infusion start. The primary end point was the difference in the incidence of migraine attacks after adenosine infusion compared with placebo. Eighteen participants completed the study. We found no difference in the incidence of migraine after adenosine infusion (7 of 18, 39%) compared with placebo (3 of 18, 17%) ( P = 0.29). Fourteen participants reported headache after adenosine infusion (14 of 18, 78%) compared with placebo (6 of 18, 33%) ( P < 0.01). Adenosine increased heart rate ( P < 0.001), facial skin blood flow ( P < 0.05), and STA diameter (AUC T0-20min , P = 0.01) and decreased V MCA (AUC T0-20min , P < 0.001) compared with placebo. Adenosine induced headache accompanied by a short-lasting (<30 minutes) dilation of intracerebral and extracerebral arteries. The nonsignificant migraine induction might be because of the presence of several adenosine receptors with counteracting signaling, highlighting the need of more selective modulators to dissect the implication of adenosine in migraine.
KW - Humans
KW - Vasodilation
KW - Adenosine/adverse effects
KW - Cross-Over Studies
KW - Headache
KW - Migraine Disorders/drug therapy
KW - Double-Blind Method
U2 - 10.1097/j.pain.0000000000002804
DO - 10.1097/j.pain.0000000000002804
M3 - Journal article
C2 - 36251971
VL - 164
SP - 1118
EP - 1127
JO - Pain
JF - Pain
SN - 0304-3959
IS - 5
ER -
ID: 343583429